ALEXANDER E PERL MD
Prescription History 1801824321
Internal Medicine - Medical Oncology in Philadelphia, PA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ALEXANDER E PERL MD, an active Medical Oncology specialist practicing in Philadelphia, PA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 105 documented patient claims. Among these therapy options, the most frequently utilized medication is Acyclovir, which accounts for 33 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other PA PrescribersVs. PA Avg |
|---|---|---|---|
| Acyclovir | 33 | $30.51 | ≈ Typical |
About Acyclovir: Acyclovir is used to treat infections caused by certain types of viruses. Show more ▾ It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections. A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. In 2023, this provider wrote 33 Medicare prescriptions for Acyclovir, about 1.2 times the volume of the typical Pennsylvania prescriber of this medication (27). Medicare paid an average of $30.51 per fill, versus $26.32 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 55 30-Day Fills standardized to 30-day supplies 1,650 Days of Medication total across all patients in 2023 | |||
| XospataGilteritinib Fumarate | 21 | $17,002.81▼ below PA avg | ≈ Typical |
About Xospata: Gilteritinib is used to treat acute myeloid leukemia (AML). Show more ▾ It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 21 Medicare prescriptions for Xospata, about the same volume as the typical Pennsylvania prescriber of this medication (20). Medicare paid an average of $17,002.81 per fill, versus $22,156.60 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the PA average for this medication. 21 30-Day Fills standardized to 30-day supplies 621 Days of Medication total across all patients in 2023 | |||
| SprycelDasatinib | 14 | $6,936.95▼ below PA avg | ≈ Typical |
About Sprycel: This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). Show more ▾ It works by slowing or stopping the growth of cancer cells. A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. In 2023, this provider wrote 14 Medicare prescriptions for Sprycel, about 82% of the volume of the typical Pennsylvania prescriber of this medication (17). Medicare paid an average of $6,936.95 per fill, versus $13,106.26 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the PA average for this medication. 14 30-Day Fills standardized to 30-day supplies 420 Days of Medication total across all patients in 2023 | |||
| TasignaNilotinib Hcl | 13 | $19,819.68 | ≈ Typical |
About Tasigna: Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). Show more ▾ It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 13 Medicare prescriptions for Tasigna, about 87% of the volume of the typical Pennsylvania prescriber of this medication (15). Medicare paid an average of $19,819.68 per fill, versus $14,637.86 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 13 30-Day Fills standardized to 30-day supplies 364 Days of Medication total across all patients in 2023 | |||
| Imatinib Mesylate | 12 | $110.62▼ below PA avg | ▼ Less than typical |
About Imatinib Mesylate: This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). Show more ▾ It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome). A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors. In 2023, this provider wrote 12 Medicare prescriptions for Imatinib Mesylate, about half the volume of the typical Pennsylvania prescriber of this medication (22). Medicare paid an average of $110.62 per fill, versus $2,955.57 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the PA average for this medication. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2023 | |||
| Levofloxacin | 12 | $14.54 | ▼ Less than typical |
About Levofloxacin: This medication is used to treat a variety of bacterial infections. Show more ▾ Levofloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. Levofloxacin injection is used if you cannot take the medication by mouth. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. The L-isomer of Ofloxacin. In 2023, this provider wrote 12 Medicare prescriptions for Levofloxacin, about half the volume of the typical Pennsylvania prescriber of this medication (23). Medicare paid an average of $14.54 per fill, versus $9.03 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average PA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 311 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for ALEXANDER E PERL MD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Medical Oncology prescribing approach at this Philadelphia, PA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among PA prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
